Here we investigated the efficacy of different antibiotics to kill P. aeruginosa in biofilms. Strain PAO1 was grown in the Calgary device to 8.9×107 CFU. At MICs, colistin sulfate, colistimethat, tobramycin or colistin sulfate/tobramycin reduced bacterial numbers to 6.5×104, 1.1×105, 1.2×105 and 3.5×104 CFUs/ml, respectively. At 2×MICs numbers were reduced to 3.9×104, 4.6×104, 7.0×104 and 4.0×102 CFU/ml, respectively. In flow cells 4-day-old GFP-labeled PAO1 biofilms were incubated for 24 and 48 h without and with addition of 10×MICs of colistin sulfate, tobramycin or colistin sulfate/tobramycin to the medium, and the bacterial killing rate was determined using propidium iodide and the COMSTAT software. Addition of colistin sulfate, tobramycin or colistin sulfate/tobramycin killed 84.2%, 8.4% and 99.5% of P. aeruginosa after 24 h, and 77.9%, 35.5% and 98.8% after 48 h, respectively. Three-dimensional fluorescence imaging of the P. aeruginosa biofilm incubated with the various antibiotics allowed localization of dead and surviving bacteria in the 'mushroom' structures: while colistin sulfate killed predominantly the stalk population, tobramycin killed the cap population. The colistin sulfate/tobramycin combination killed both populations equally. Thus, colistin sulfate and tobramycin allow efficient killing of P. aeruginosa and suggest that simultaneous combination therapy in CF patients is more efficient than alternative single antibiotic therapy with these drugs to combat lung disease in CF. Supported by Grünenthal, Aachen, Germany.
